OxVax Company
OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Founded Date:
2021-01-01
Last Funding Type:
Seed
Headquarters:
Oxford, Oxfordshire, United Kingdom
Investors Number:
2
Industry:
Dendritic Cells
Last Funding Date:
2021-04-21
Funding Status:
Seed